Premium
Respiratory syndrome coronavirus‐2 response: Microbiota as lactobacilli could make the difference
Author(s) -
Zrelli Samia,
Amairia Safa,
Zrelli Malek
Publication year - 2021
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.26746
Subject(s) - coronavirus , virology , biology , virus , immune system , immunology , viral replication , respiratory system , covid-19 , microbiology and biotechnology , penetration (warfare) , medicine , disease , infectious disease (medical specialty) , pathology , anatomy , operations research , engineering
Coronavirus disease 2019 (COVID‐19) is caused by respiratory syndrome coronavirus qualified as SARS‐CoV‐2. Viral penetration requires binding of the viral spike (S) protein to a specific cellular receptor (ACE2) highly expressed in a nasal goblet and ciliated cells. In several countries, the COVID‐19 evolution was relatively benign compared to others and despite noncompliance with health recommendations on several occasions. In this overview, we attempt to define the criteria that could explain such a difference. Among these criteria, the specificity of Lactobacillus genus strains, as a part of nasal microbiota, could play a role of a barrier against viral penetration and could strengthen the host's immune system in some populations rather than others. In fact, several studies have shown the role of lactic acid bacteria, including lactobacilli, in the prevention of viral respiratory infections. This could provide important information on a possible mechanism of the virus spreading.